Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

New Jersey-based Kenvue Inc. (KVUE) is a consumer health company operating across the Americas, Europe, EMEA, and the ...

Kenvue Inc. (NYSE:KVUE) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company names an interim CEO and ...

Kenvue stock surged Monday after the company — known for brands like Tylenol — announced sweeping changes, including naming a new CEO.

American consumer health company Kenvue's Board of Directors announced new actions to unlock shareholder value and an interim ...

Band-Aid and Tylenol maker Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, laying what some investors expect will be the groundwork for an eventual sale of the ...

Kenvue’s other brands include Aveeno, Band-Aid, Zyrtec, Neosporin, and Neutrogena. The company, led by CEO Thibaut Mongon, recorded over $15 billion in net sales in 2023.

Kenvue's stock is trading at $23.20, comfortably above key moving averages. The eight-day simple moving average sits at $22.33, the 20-day SMA is $21.87 and the 50-day SMA trails at $19.94.

BAND-AID and Tylenol maker Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, laying what some investors expect will be the groundwork for an eventual sale of the ...

Kenvue, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, named director Kirk Perry as interim chief executive officer as Thibaut Mongon departs the company.

Kenvue CEO Thibaut Mongon has stepped down as the company’s chief executive and departed its board of directors. The CEO of Tylenol maker Kenvue ( KVUE) has left the company as part of an internal ...

Reuters FILE PHOTO: Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson's consumer-health business, speaks during an interview with CNBC during his company's IPO at the New York Stock Exchange ...